Document is current
Any future updates will be listed below
-
Authors
Hao, Yun
Xie, Fei
Zhou, Yongjie
Li, Chuan
Zhang, Xiaoyun
Shen, Junyi
Yao, Minghong
Sun, Xin
Zhou, Jin
Wen, Tianfu
Peng, Wei https://orcid.org/0000-0002-5780-2157
-
Funding
Funding for this research was provided by:
West China Hospital, Sichuan University (2022HXFH012)
Natural Science Foundation of Sichuan Province (2024NSFSC0637)
- License Information
-
More Information
Article History
Received: 20 March 2024
Accepted: 15 July 2024
First Online: 19 July 2024
Declarations
:
: The Ethics Committee on Biomedical Research of West China Hospital, Sichuan University, approved this study (No. 2023-1825). All participants will provide written informed consent before engaging in any study activities.
: Not applicable - No identifying images or other personal or clinical details of participants are presented here or will be included in the trial results report. Informed consent materials are in Chinese and are available from the corresponding author upon request.
: WP reported receiving lecture fees from Hengrui, Merk, Roche, Eisai, and Innovent. CL, XYZ, and JYS reported receiving lecture fees from Merk, Bayer, Roche, and Hengrui. TFW received grant support from AstraZeneca, Zelgen, Merk, Roche, Eisai, and Innovent, advisory board fees, and lecture fees from Bayer, Merk, Roche, and Hengrui. Camrelizumab and apatinib mentioned in the study design were manufactured by Hengrui, while the above-mentioned companies were not involved in the study design, data collection, management, analysis and interpretation, report writing, or the decision to submit the report for publication. The ultimate decision-making authority for this study rests with the authors. No other potential conflict of interest was reported.
